Skip to content
Tuesday 18 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,728.04
+0.07%
DAX
26,128.36
-0.80%
CAC 40
8,509.36
-0.82%
STOXX 50
6,468.17
-0.95%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Monday 31 August 2015 11:50 pm

Google teams up with French drugmaker Sanofi to improve diabetes treatment

By: Joe Hall

Add as a preferred source on Google

Google will team up with French drugmaker Sanofi SA to create new digital technologies that aim to improve diabetes treatment.

Read more: Google and Novartis join forces to develop contact lens for diabetics

Google Life Sciences – soon to become its own business under Google's Alphabet holding company – will collaborate with Sanofi explore how diabetes care can be improved, better understood and made more cost effective with new tools and technology.
 
The company, founded to expand Google’s influence beyond the internet, has previously collaborated with a number of pharmaceutical companies on reaching healthcare solutions.
 
It has developed a contact lens to help diabetics track blood glucose levels with Novartis AG and created a wearable continuous glucose-monitoring device in collaboration with DexCom Inc.
 
Chief executive of the life sciences team, Andy Conrad, said: “With new technologies emerging to provide a more continuous and real-time view of a patient’s health, we can see the promise for more proactive and effective ways to control diabetes.
 
“Together with Sanofi, we believe diabetes management can be simpler and more convenient, which may help patients achieve an improved quality of life.”
 
Sales of diabetes treatments accounted for around 20 per cent of Sanofi's €9.4bn (£6.9bn) total sales in the second quarter, but the firm has struggled to gain access into the US market for its diabetes medications.
 
The company’s chief executive Olivier Brandicourt MD said the firm’s “first-of-its-kind” partnership with Google had the potential to “transform” care for the condition which is expected to affect 592m people by 2035, according to the International Diabetes Federation.
 

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Tech

Related Topics

  • Google

Trending Articles

  • As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

  • US bond market jitters spark UK economy recession warning

  • Monzo chair makes early exit after boardroom rift

  • Aldi boss wades into supermarket ‘price-gouging’ row

  • Jobless Banquet: Youth unemployment surge ‘sends Neets to KFC’

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • This Is the Moment Everything Changed: Ascensia Launches Global Art and Photography Competition for World Diabetes Day

    Business Wire
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss

    Business Wire
  • ActiveCampaign Launches Google Ads Connector for Active Intelligence, Bringing AI-Guided Campaign Creation and Reporting to Marketers

    Business Wire
  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Google backs publisher model as Apple considers price tag for news

    Media
    AI copyright laws
  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook